Spots Global Cancer Trial Database for Cervical Cancer Screening With NGS-HPV Technology Based on Menstrual Blood

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Cervical Cancer Screening With NGS-HPV Technology Based on Menstrual Blood

Official Title: Cervical Cancer Screening With NGS-HPV Technology Based on Menstrual Blood

Study ID: NCT06082765

Conditions

Cervical Cancer

Interventions

Study Description

Brief Summary: Our study is conducted to recruit cervical cancer screening patients to evaluate the application value of using high-throughput sequencing technology to detect HPV in menstrual blood for cervical cancer screening.

Detailed Description: Our study aims to recruit 10,000 cervical cancer screening patients from the outpatient department of Zhongnan Hospital of Wuhan University from September 1, 2023 to March 31, 2028. The procedures were conducted as below: (1) Conduct cervical cancer screening (TCT+cobas-HPV) for all the participants. (2) Collect sanitary napkins from participants during their first menstrual period after cervical HPV testing. (3) Detect HPV using high-throughput sequencing technology in the menstrual blood (MB) from sanitary napkins. (4) Colposcopy referral (biopsy if necessary) for patients with abnormal screening results. (5) Compare the concordance between MB-HPV and cobas-HPV.